S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Stock market today: Asian stocks follow Wall St up after strong US jobs report
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Apple is expected to unveil a sleek, pricey headset. Is it the device VR has been looking for?
US Navy says Iran Revolutionary Guard fast-attack boats 'harassed' ship in Strait of Hormuz
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
Greek authorities rescue 91 migrants from river islet on border with Turkey
Chuck Todd says he's leaving 'Meet the Press' after a tumultuous near-decade moderating the NBC political panel show
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Saudi Arabia to reduce oil output by 1 million barrels per day, while rest of OPEC+ extends previous cuts through 2024
Switzerland's UBS says it could complete Credit Suisse takeover on June 12

Biogen (BIIB) Stock Forecast, Price & News

$300.20
-2.21 (-0.73%)
(As of 06/2/2023 08:48 PM ET)
Compare
Today's Range
$297.68
$303.17
50-Day Range
$269.98
$318.06
52-Week Range
$188.54
$319.74
Volume
817,100 shs
Average Volume
972,839 shs
Market Capitalization
$43.45 billion
P/E Ratio
13.94
Dividend Yield
N/A
Price Target
$328.92

Biogen MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.81 Rating Score
Upside/​Downside
9.6% Upside
$328.92 Price Target
Short Interest
Healthy
2.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.89
Upright™ Environmental Score
News Sentiment
0.42mentions of Biogen in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$982,911 Sold Last Quarter
Proj. Earnings Growth
6.04%
From $15.40 to $16.33 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.20 out of 5 stars

Medical Sector

325th out of 980 stocks

Biological Products, Except Diagnostic Industry

46th out of 163 stocks


BIIB stock logo

About Biogen (NASDAQ:BIIB) Stock

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Stock News Headlines

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential (BIIB)
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Biogen (NASDAQ:BIIB) PT Raised to $360.00
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Medicare Plans to Cover Alzheimer’s Drugs
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Goldman Sachs Remains a Buy on Biogen (BIIB)
Biogen (BIIB) Receives a Buy from Mizuho Securities
Analyst Ratings for Biogen
See More Headlines

BIIB Price History

BIIB Company Calendar

Last Earnings
4/25/2023
Today
6/05/2023
Next Earnings (Estimated)
7/19/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:BIIB
CUSIP
09062X10
Employees
8,725
Year Founded
1978

Price Target and Rating

Average Stock Price Forecast
$328.92
High Stock Price Forecast
$371.00
Low Stock Price Forecast
$263.00
Forecasted Upside/Downside
+9.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.81
Research Coverage
26 Analysts

Profitability

Net Income
$3.05 billion
Pretax Margin
36.45%

Debt

Sales & Book Value

Annual Sales
$10.17 billion
Cash Flow
$21.52 per share
Book Value
$95.25 per share

Miscellaneous

Free Float
143,801,000
Market Cap
$43.45 billion
Optionable
Optionable
Beta
0.18

Social Links


Key Executives

  • Christopher A. Viehbacher
    President, Chief Executive Officer & Director
  • Nicole Murphy
    Head-Pharmaceutical Operations & Technology
  • Michael R. McDonnell
    Chief Financial Officer & Executive Vice President
  • Mahalakshmi Radhakrishnan
    Chief Medical Officer & Group Senior VP
  • Priya Singhal
    Executive VP, Head-Research & Development













BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 5 hold ratings and 21 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BIIB shares.
View BIIB analyst ratings
or view top-rated stocks.

What is Biogen's stock price forecast for 2023?

26 brokerages have issued 1-year price targets for Biogen's shares. Their BIIB share price forecasts range from $263.00 to $371.00. On average, they predict the company's share price to reach $328.92 in the next twelve months. This suggests a possible upside of 9.6% from the stock's current price.
View analysts price targets for BIIB
or view top-rated stocks among Wall Street analysts.

How have BIIB shares performed in 2023?

Biogen's stock was trading at $276.92 at the beginning of 2023. Since then, BIIB stock has increased by 8.4% and is now trading at $300.20.
View the best growth stocks for 2023 here
.

Are investors shorting Biogen?

Biogen saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 2,960,000 shares, an increase of 30.4% from the April 30th total of 2,270,000 shares. Based on an average daily volume of 905,900 shares, the short-interest ratio is presently 3.3 days. Currently, 2.1% of the company's stock are short sold.
View Biogen's Short Interest
.

When is Biogen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 19th 2023.
View our BIIB earnings forecast
.

How were Biogen's earnings last quarter?

Biogen Inc. (NASDAQ:BIIB) announced its quarterly earnings data on Tuesday, April, 25th. The biotechnology company reported $3.40 EPS for the quarter, topping analysts' consensus estimates of $3.25 by $0.15. The biotechnology company had revenue of $2.46 billion for the quarter, compared to analysts' expectations of $2.34 billion. Biogen had a trailing twelve-month return on equity of 19.60% and a net margin of 30.99%. The company's revenue was down 2.7% compared to the same quarter last year. During the same quarter last year, the business earned $3.62 earnings per share.
Read the conference call transcript
.

What guidance has Biogen issued on next quarter's earnings?

Biogen issued an update on its FY 2023 earnings guidance on Thursday, April, 27th. The company provided EPS guidance of $15.00-$16.00 for the period, compared to the consensus EPS estimate of $15.48. The company issued revenue guidance of -.

What is Michel Vounatsos' approval rating as Biogen's CEO?

394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).

What is Biogen's stock symbol?

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Who are Biogen's major shareholders?

Biogen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.66%), State Street Corp (4.67%), Wellington Management Group LLP (3.77%), Geode Capital Management LLC (2.14%), Envestnet Asset Management Inc. (1.77%) and Price T Rowe Associates Inc. MD (1.44%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends
.

How do I buy shares of Biogen?

Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biogen's stock price today?

One share of BIIB stock can currently be purchased for approximately $300.20.

How much money does Biogen make?

Biogen (NASDAQ:BIIB) has a market capitalization of $43.45 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $21.54 on an earnings per share basis.

How many employees does Biogen have?

The company employs 8,725 workers across the globe.

Does Biogen have any subsidiaries?
The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -